We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00969813
First Posted: September 1, 2009
Last Update Posted: February 11, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Pfizer
  Purpose
This study is designed to evaluate how CP-690,550 is handled by the body in healthy volunteers who have mild and moderate hepatic impairment compared to healthy volunteers with normal hepatic function. This study will also evaluate the safety and tolerability of CP-690,550.

Condition Intervention Phase
Hepatic Insufficiency Drug: CP-690,550 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A Phase 1, Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Pharmacokinetics of CP-690,550 in subjects with hepatic impairment compared to subjects with normal hepatic function [ Time Frame: 3 days ]

Secondary Outcome Measures:
  • Safety and tolerability of CP-690,550 in subjects with hepatic impairment compared to subjects with normal hepatic function [ Time Frame: 10-14 days ]

Enrollment: 18
Study Start Date: November 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Normal hepatic function Drug: CP-690,550
Single 10 mg dose of CP-690,550
Experimental: Mild hepatic impairment Drug: CP-690,550
Single 10 mg dose of CP-690,550
Experimental: Moderate hepatic impairment Drug: CP-690,550
Single 10 mg dose of CP-690,550

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers who have normal liver function, and subjects who have either mild or moderate liver impairment.

Exclusion Criteria:

  • Subjects with severe liver impairment
  • Subjects who have weakened immune systems
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00969813


Locations
United States, Florida
Pfizer Investigational Site
South Miami, Florida, United States, 33143
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00969813     History of Changes
Other Study ID Numbers: A3921015
First Submitted: August 31, 2009
First Posted: September 1, 2009
Last Update Posted: February 11, 2010
Last Verified: February 2010

Keywords provided by Pfizer:
Hepatic impairment

Additional relevant MeSH terms:
Liver Diseases
Hepatic Insufficiency
Digestive System Diseases
Tofacitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action